Mombu the Medicine Forum sponsored links

Go Back   Mombu the Medicine Forum > Medicine > The Guradian: Pharma hires ghostwriters (psychiatric psychiatry stomach heart job)
User Name
Password
REGISTER NOW! Mark Forums Read

sponsored links


Reply
 
1 11th May 10:25
rita stanley
External User
 
Posts: 1
Default The Guradian: Pharma hires ghostwriters (psychiatric psychiatry stomach heart job)


http://observer.guardian.co.uk/uk_news/story/0,6903,1101680,00.html

Revealed: how drug firms 'hoodwink' medical journals

Pharmaceutical giants hire ghostwriters to produce articles - then put
doctors' names on them

Antony Barnett, public affairs editor
Sunday December 7, 2003
The Observer

Observer inquiry reveals.
The journals, bibles of the profession, have huge influence on which drugs
doctors prescribe and the treatment hospitals provide. But The Observer has
uncovered evidence that many articles written by so-called independent
academics may have been penned by writers working for agencies which receive
huge sums from drug companies to plug their products.

Estimates suggest that almost half of all articles published in journals are
by ghostwriters. While doctors who have put their names to the papers can be
paid handsomely for 'lending' their reputations, the ghostwriters remain
hidden. They, and the involvement of the pharmaceutical firms, are rarely
revealed.

These papers endorsing certain drugs are paraded in front of GPs as
independent research to persuade them to prescribe the drugs.

In February the New England Journal of Medicine was forced to retract an
article published last year by doctors from Imperial College in London and
the National Heart Institute on treating a type of heart problem. It emerged
that several of the listed authors had little or nothing to do with the
research. The deception was revealed only when German cardiologist Dr Hubert
Seggewiss, one of the eight listed authors, called the editor of the journal
to say he had never seen any version of the paper.

An article published last February in the Journal of Alimentary Pharmacology
, which specialises in stomach disorders, involved a medical writer working
for drug giant AstraZeneca - a fact that was not revealed by the author.

The article, by a German doctor, acknowledged the 'contribution' of Dr
Madeline Frame, but did not admit that she was a senior medical writer for
AstraZeneca. The article essentially supported the use of a drug called
Omeprazole - which is manufactured by AstraZeneca - for gastric ulcers,
despite suggestions that it gave rise to more adverse reactions than similar
drugs.

Few within the industry are brave enough to break cover. However, Susanna
Rees, an editorial assistant with a medical writing agency until 2002, was
so concerned about what she witnessed that she posted a letter on the
British Medical Journal website.

'Medical writing agencies go to great lengths to disguise the fact that the
papers they ghostwrite and submit to journals and conferences are
ghostwritten on behalf of pharmaceutical companies and not by the named
authors,' she wrote. 'There is a relatively high success rate for
ghostwritten submissions - not outstanding, but consistent.'

Rees said part of her job had been to ensure that any article that was
submitted electronically would give no clues as to the origin of the
research.

'One standard procedure I have used states that before a paper is submitted
to a journal electronically or on disc, the editorial assistant must open
the file properties of the Word do***ent manuscript and remove the names of
the medical writing agency or agency ghostwriter or pharmaceutical company
and replace these with the name and institution of the person who has been
invited by the pharmaceutical drug company (or the agency acting on its
behalf) to be named as lead author, but who may have had no actual input
into the paper,' she wrote.

When contacted, Rees declined to give any details. 'I signed a
confidentiality agreement and am unable to comment,' she said.

A medical writer who has worked for a number of agencies did not want to be
identified for fear he would not get any work again.

'It is true that sometimes a drug company will pay a medical writer to write
a review article supporting a particular drug,' he said. 'This will mean
using all published information to write an article explaining the benefits
of a particular treatment.

'A recognised doctor will then be found to put his or her name to it and it
will be submitted to a journal without anybody knowing that a ghostwriter or
a drug company is behind it. I agree this is probably unethical, but all the
firms are at it.'

One field where ghostwriting is becoming an increasing problem is
psychiatry.

Dr David Healy, of the University of Wales, was doing research on the
possible dangers of anti-depressants, when a drug manufacturer's
representative emailed him with an offer of help.

The email, seen by The Observer, said: 'In order to reduce your workload to
a minimum, we have had our ghostwriter produce a first draft based on your
published work. I attach it here.'

The article was a 12-page review paper ready to be presented at an
forthcoming conference. Healy's name appeared as the sole author, even
though he had never seen a single word of it before. But he was unhappy with
the glowing review of the drug in question, so he suggested some changes.

The company replied, saying he had missed some 'commercially important'
points. In the end, the ghostwritten paper appeared at the conference and in
a psychiatric journal in its original form - under another doctor's name.

Healy says such deception is becoming more frequent. 'I believe 50 per cent
of articles on drugs in the major medical journals are not written in a way
that the average person would expect them to be... the evidence I have seen
would suggest there are grounds to think a significant proportion of the
articles in journals such as the New England Journal of Medicine, the
British Medical Journal and the Lancet may be written with help from medical
writing agencies,' he said. 'They are no more than infomercials paid for by
drug firms.'

In the United States a legal case brought against drug firm Pfizer turned up
internal company do***ents showing that it employed a New York medical
writing agency. One do***ent ****yses articles about the anti-depressant
Zoloft. Some of the articles lacked only one thing: a doctor's name. In the
margin the agency had put the initials TBD, which Healy assumes means 'to be
determined'.

Dr Richard Smith, editor of the British Journal of Medicine, admitted
ghostwriting was a 'very big problem' .

'We are being hoodwinked by the drug companies. The articles come in with
doctors' names on them and we often find some of them have little or no idea
about what they have written,' he said.

'When we find out, we reject the paper, but it is very difficult. In a
sense, we have brought it on ourselves by insisting that any involvement by
a drug company should be made ********. They have just found ways to get
round this and go undercover.'

Special reports
Medicine and health

Useful links
British Medical Association
Department of Health
General Medical Council
Health on the Net Foundation
Institute of Cancer Research
Medical Research Council
NHS Direct
World Health Organisation
  Reply With Quote


  sponsored links


Reply


Thread Tools
Display Modes




Copyright 2006 SmartyDevil.com - Dies Mies Jeschet Boenedoesef Douvema Enitemaus -
666